Pde4C — Phosphodiesterase 4C is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Phosphodiesterase 4C | |
|---|---|
| Gene Symbol | PDE4C |
| Full Name | Phosphodiesterase 4C |
| Chromosome | 19q13.12 |
| NCBI Gene ID | 5144 |
| OMIM | 610172 |
| Ensembl ID | ENSG00000074527 |
| UniProt ID | Q08431 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Asthma, COPD |
PDE4C (Phosphodiesterase 4C) is a cAMP-specific phosphodiesterase that plays a critical role in regulating intracellular cAMP levels. The gene is located on chromosome 19q13.12 and encodes a protein of approximately 68 kDa. While PDE4C was initially characterized for its role in airway smooth muscle function and inflammatory responses, emerging evidence demonstrates important functions in the central nervous system, particularly in modulating synaptic plasticity, memory formation, and emotional regulation.
PDE4C belongs to the phosphodiesterase type 4 family, which specifically hydrolyzes cAMP and is distinguished by its expression pattern and regulation. The PDE4 family (including subtypes PDE4A, PDE4B, PDE4C, and PDE4D) is a major target for drug development, with several inhibitors approved for clinical use in inflammatory and respiratory diseases.
The PDE4C gene contains multiple exons and gives rise to alternatively spliced variants. The gene promoter contains response elements for various transcription factors, including CREB, allowing activity-dependent regulation in neurons. The upstream conserved regions (UCR) in the protein product provide additional regulatory complexity.
PDE4C exhibits a distinctive expression pattern:
In the brain, PDE4C is expressed in:
The PDE4C protein contains key structural elements:
PDE4C specifically hydrolyzes:
The enzyme is constitutively active, but its activity can be modulated by:
PDE4C plays a crucial role in neuronal cAMP signaling:
PDE4C modulates synaptic plasticity through cAMP regulation:
PDE4C contributes to circadian regulation of cAMP in the suprachiasmatic nucleus:
PDE4C has significant implications for Alzheimer's disease:
| Aspect | Mechanism | Evidence |
|---|---|---|
| Memory deficits | Elevated PDE4 activity reduces cAMP, impairing synaptic plasticity | PDE4 inhibitors improve memory in AD models |
| Amyloid pathology | cAMP dysregulation affects amyloid precursor protein processing | Altered PDE4 expression in AD brain |
| Tau pathology | cAMP/PKA signaling influences tau phosphorylation | PDE4 inhibition reduces tau pathology |
| Therapeutic potential | PDE4 inhibitors as cognitive enhancers | Clinical trials in progress |
In Parkinson's disease, PDE4C affects:
PDE4C variants have been associated with:
The well-established role of PDE4C in:
Several PDE4 inhibitors have been developed:
| Inhibitor | Approval Status | Indications | CNS Penetration |
|---|---|---|---|
| Roflumilast | Approved (FDA/EMA) | COPD | Low |
| Apremilast | Approved (FDA/EMA) | Psoriasis, PsA | Low |
| Ibudilast | Approved (Japan) | Asthma, COPD | Moderate |
| Rolapitant | Approved (FDA) | CINV | N/A |
Newer PDE4 inhibitors are being developed with improved brain penetration:
PDE4 inhibition is explored for:
PDE4C interacts with multiple pathways:
PDE4C forms complexes with:
Pde4c knockout mice show:
PDE4 inhibitor studies in models demonstrate:
PDE4C polymorphisms have been linked to:
PDE4C expression may serve as:
Current research focuses on:
The study of Pde4C — Phosphodiesterase 4C has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.